Markers for COVID-19 disease progression: Comprehensive LC-MS characterization of the metabolome with the Xevo G3 QTof

During this webinar you’ll learn about the recently launched Xevo G3 QTof system and discover how it's solving problems that matter.

Professor Clare Mills discusses the use of an LC/MS metabolomics approach to profile serum from COVID-19 inpatients. Here they describe how to identify and characterize prognostic biomarkers to support the development of mass spectrometry rapid clinical screening tools.

Tune in to hear more about how the team are planning to characterize immune disfunction as a consequence of SARS-CoV-2 infection.

Key learning objectives

• Discover how the new Xevo G3 QTof system provides comprehensive characterization of analytes
• Develop an understanding of LC/MS and its use in metabolomic and lipidomic studies
• Delve into the world of omics, identifying statistically relevant markers for disease and the impact on patients

Who should attend?

• Scientists interested in characterizing a range of analytes with LC/MS
• Lab managers who want high-throughput, benchtop QTof technology that helps solve problems in their lab

Certificate of attendance

All webinar participants can request a certificate of attendance, including a learning outcomes summary, for continuing education purposes.